Skip to main content
Top
Published in: Journal of Endocrinological Investigation 9/2016

01-09-2016 | Original Article

Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children

Authors: A. Ciresi, G. Pizzolanti, M. Leotta, V. Guarnotta, G. Teresi, C. Giordano

Published in: Journal of Endocrinological Investigation | Issue 9/2016

Login to get access

Abstract

Purpose

The effect of growth hormone (GH) on adipose tissue and the role of adipokines in modulating metabolism are documented, but with discordant data. Our aim was to evaluate the impact of GH treatment on a series of selected adipokines known to have a metabolic role and poorly investigated in this setting.

Methods

This is a prospective study. Thirty-one prepubertal children (25 M, 6 F; aged 8.5 ± 1.6 years) with isolated GH deficiency treated with GH for at least 12 months and 30 matched controls were evaluated. Auxological and metabolic parameters, insulin sensitivity indexes, leptin, soluble leptin receptor, adiponectin, visfatin, resistin, omentin, adipocyte fatty acid-binding protein and retinol-binding protein-4 were evaluated before and after 12 months of treatment.

Results

At baseline, no significant difference in metabolic parameters was found between GHD children and controls, except for higher LDL cholesterol (p = 0.004) in the first group. At multivariate analysis, LDL cholesterol was independently associated with resistin (B 0.531; p = 0.002), while IGF-I was the only variable independently associated with visfatin (B 0.688; p < 0.001). After 12 months, a significant increase in fasting insulin (p = 0.008), Homa-IR (p = 0.007) and visfatin (p < 0.001) was found, with a concomitant decrease in LDL cholesterol (p = 0.015), QUICKI (p = 0.001), ISI Matsuda (p = 0.006), leptin (p = 0.015) and omentin (p = 0.003)]. At multivariate analysis, BMI was the only variable independently associated with leptin (B 0.485; p = 0.040).

Conclusions

GH treatment modifies adipokine secretion and the perturbation of some adipokine levels could contribute to the clinical and metabolic changes observed during the follow-up.
Literature
1.
go back to reference Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S et al (2010) Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res 20(1):1–7CrossRefPubMed Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S et al (2010) Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res 20(1):1–7CrossRefPubMed
2.
go back to reference Cantley J (2014) The control of insulin secretion by adipokines: current evidence for adipocyte-beta cell endocrine signalling in metabolic homeostasis. Mamm Genome 2:442–454CrossRef Cantley J (2014) The control of insulin secretion by adipokines: current evidence for adipocyte-beta cell endocrine signalling in metabolic homeostasis. Mamm Genome 2:442–454CrossRef
3.
go back to reference Capalbo D, Esposito A, Di Mase R et al (2012) Update on early cardiovascular and metabolic risk factors in children and adolescents affected with growth hormone deficiency. Minerva Endocrinol 37:379–389PubMed Capalbo D, Esposito A, Di Mase R et al (2012) Update on early cardiovascular and metabolic risk factors in children and adolescents affected with growth hormone deficiency. Minerva Endocrinol 37:379–389PubMed
4.
go back to reference Salerno M, Esposito V, Farina V et al (2006) Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after 2 years of GH replacement therapy: an observational, open, prospective, case-control study. J Clin Endocrinol Metab 91:1288–1295CrossRefPubMed Salerno M, Esposito V, Farina V et al (2006) Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after 2 years of GH replacement therapy: an observational, open, prospective, case-control study. J Clin Endocrinol Metab 91:1288–1295CrossRefPubMed
5.
go back to reference van der Sluis IM, Boot AM, Hop WC et al (2002) Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: a 6-year follow-up study. Horm Res 58:207–214CrossRefPubMed van der Sluis IM, Boot AM, Hop WC et al (2002) Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: a 6-year follow-up study. Horm Res 58:207–214CrossRefPubMed
6.
go back to reference Nørrelund H, Gravholt CH, Englaro P et al (1998) Increased levels but preserved diurnal variation of serum leptin in GH-deficient patients: lack of impact of different modes of GH administration. Eur J Endocrinol 138:644–652CrossRefPubMed Nørrelund H, Gravholt CH, Englaro P et al (1998) Increased levels but preserved diurnal variation of serum leptin in GH-deficient patients: lack of impact of different modes of GH administration. Eur J Endocrinol 138:644–652CrossRefPubMed
7.
go back to reference Elimam A, Lindgren AC, Norgren S et al (1999) Growth hormone treatment downregulates serum leptin levels in children independent of changes in body mass index. Horm Res 52:66–72CrossRefPubMed Elimam A, Lindgren AC, Norgren S et al (1999) Growth hormone treatment downregulates serum leptin levels in children independent of changes in body mass index. Horm Res 52:66–72CrossRefPubMed
8.
go back to reference Gill MS, Toogood AA, Jones J et al (1999) Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency. J Clin Endocrinol Metab 84:1288–1295PubMed Gill MS, Toogood AA, Jones J et al (1999) Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency. J Clin Endocrinol Metab 84:1288–1295PubMed
9.
go back to reference Edén Engström B, Burman P, Holdstock C et al (2003) Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J Clin Endocrinol Metab 88:5193–5198CrossRefPubMed Edén Engström B, Burman P, Holdstock C et al (2003) Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J Clin Endocrinol Metab 88:5193–5198CrossRefPubMed
10.
go back to reference Hana V, Silha JV, Justova V et al (2004) The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol (Oxf) 60:442–450CrossRef Hana V, Silha JV, Justova V et al (2004) The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol (Oxf) 60:442–450CrossRef
11.
go back to reference Ciresi A, Amato MC, Criscimanna A et al (2007) Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol 156:353–360CrossRefPubMed Ciresi A, Amato MC, Criscimanna A et al (2007) Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol 156:353–360CrossRefPubMed
12.
go back to reference López-Siguero JP, López-Canti LF, Espino R et al (2011) Effect of recombinant growth hormone on leptin, adiponectin, resistin, interleukin-6, tumor necrosis factor-α and ghrelin levels in growth hormone-deficient children. J Endocrinol Invest 34:300–306CrossRefPubMed López-Siguero JP, López-Canti LF, Espino R et al (2011) Effect of recombinant growth hormone on leptin, adiponectin, resistin, interleukin-6, tumor necrosis factor-α and ghrelin levels in growth hormone-deficient children. J Endocrinol Invest 34:300–306CrossRefPubMed
13.
go back to reference Growth Hormone Research Society (2000) Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 85:3990–3993 Growth Hormone Research Society (2000) Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 85:3990–3993
14.
go back to reference Greulich W, Pyle S (1959) Radiographic atlas of skeletal development of the hand and wrist, 2nd edn. Stanford University Press, Stanford Greulich W, Pyle S (1959) Radiographic atlas of skeletal development of the hand and wrist, 2nd edn. Stanford University Press, Stanford
15.
go back to reference Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
16.
go back to reference Katz A, Nambi SS, Mather K et al (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402–2410CrossRefPubMed Katz A, Nambi SS, Mather K et al (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402–2410CrossRefPubMed
17.
go back to reference Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed
18.
go back to reference Shuldiner AR, Yang R, Gong DW (2001) Resistin, obesity and insulin resistance–the emerging role of the adipocyte as an endocrine organ. N Engl J Med 345:1345–1346CrossRefPubMed Shuldiner AR, Yang R, Gong DW (2001) Resistin, obesity and insulin resistance–the emerging role of the adipocyte as an endocrine organ. N Engl J Med 345:1345–1346CrossRefPubMed
19.
go back to reference Meazza C, Elsedfy HH, Pagani S et al (2014) Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. Horm Metab Res 46:219–223PubMed Meazza C, Elsedfy HH, Pagani S et al (2014) Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. Horm Metab Res 46:219–223PubMed
20.
go back to reference Svensson J, Herlitz H, Lundberg PA et al (2005) Adiponectin, leptin, and erythrocyte sodium/lithium countertransport activity, but not resistin, are related to glucose metabolism in growth hormone-deficient adults. J Clin Endocrinol Metab 90:2290–2296CrossRefPubMed Svensson J, Herlitz H, Lundberg PA et al (2005) Adiponectin, leptin, and erythrocyte sodium/lithium countertransport activity, but not resistin, are related to glucose metabolism in growth hormone-deficient adults. J Clin Endocrinol Metab 90:2290–2296CrossRefPubMed
21.
go back to reference Nozue H, Kamoda T, Matsui A (2007) Serum resistin concentrations in growth hormone-deficient children during growth hormone replacement therapy. Metabolism 56:1514–1517CrossRefPubMed Nozue H, Kamoda T, Matsui A (2007) Serum resistin concentrations in growth hormone-deficient children during growth hormone replacement therapy. Metabolism 56:1514–1517CrossRefPubMed
22.
go back to reference Ciresi A, Amato MC, Giordano C (2015) Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment. J Endocrinol Invest 38:351–359CrossRefPubMed Ciresi A, Amato MC, Giordano C (2015) Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment. J Endocrinol Invest 38:351–359CrossRefPubMed
23.
go back to reference Heptulla RA, Boulware SD, Caprio S et al (1997) Decreased insulin sensitivity and compensatory hyperinsulinemia after hormone treatment in children with short stature. J Clin Endocrinol Metab 82:3234–3238PubMed Heptulla RA, Boulware SD, Caprio S et al (1997) Decreased insulin sensitivity and compensatory hyperinsulinemia after hormone treatment in children with short stature. J Clin Endocrinol Metab 82:3234–3238PubMed
24.
go back to reference Rauch F, Westermann F, Englaro P et al (1998) Serum leptin is suppressed by growth hormone therapy in growth hormone-deficient children. Horm Res 50:18–21CrossRefPubMed Rauch F, Westermann F, Englaro P et al (1998) Serum leptin is suppressed by growth hormone therapy in growth hormone-deficient children. Horm Res 50:18–21CrossRefPubMed
25.
go back to reference Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426–430CrossRefPubMed Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426–430CrossRefPubMed
26.
go back to reference Petelin A, Bizjak M, Černelič-Bizjak M et al (2014) Low-grade inflammation in overweight and obese adults is affected by weight loss program. J Endocrinol Invest 37(8):745–755CrossRefPubMed Petelin A, Bizjak M, Černelič-Bizjak M et al (2014) Low-grade inflammation in overweight and obese adults is affected by weight loss program. J Endocrinol Invest 37(8):745–755CrossRefPubMed
27.
go back to reference Li ZP, Zhang M, Gao J et al (2014) Study of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults. Genet Mol Res 13:4050–4056CrossRefPubMed Li ZP, Zhang M, Gao J et al (2014) Study of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults. Genet Mol Res 13:4050–4056CrossRefPubMed
28.
go back to reference Ciresi A, Amato MC, Pizzolanti G et al (2015) Serum visfatin levels in acromegaly: correlation with disease activity and metabolic alterations. Growth Horm IGF Res 25:240–246CrossRefPubMed Ciresi A, Amato MC, Pizzolanti G et al (2015) Serum visfatin levels in acromegaly: correlation with disease activity and metabolic alterations. Growth Horm IGF Res 25:240–246CrossRefPubMed
29.
go back to reference Kralisch S, Fasshauer M (2013) Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 56(1):10–21CrossRefPubMed Kralisch S, Fasshauer M (2013) Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 56(1):10–21CrossRefPubMed
30.
go back to reference Graham TE, Yang Q, Blüher M et al (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354:2552–2563CrossRefPubMed Graham TE, Yang Q, Blüher M et al (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354:2552–2563CrossRefPubMed
31.
go back to reference von Eynatten M, Humpert PM (2008) Retinol-binding protein-4 in experimental and clinical metabolic disease. Expert Rev Mol Diagn 8:289–299CrossRef von Eynatten M, Humpert PM (2008) Retinol-binding protein-4 in experimental and clinical metabolic disease. Expert Rev Mol Diagn 8:289–299CrossRef
32.
go back to reference Lanes R, Soros A, Gunczler P et al (2006) Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipid and lipoproteins. J Pediatr 149:324–329CrossRefPubMed Lanes R, Soros A, Gunczler P et al (2006) Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipid and lipoproteins. J Pediatr 149:324–329CrossRefPubMed
33.
go back to reference Jaikanth C, Gurumurthy P, Cherian KM et al (2013) Emergence of omentin as a pleiotropic adipocytokine. Exp Clin Endocrinol Diabetes 121:377–383CrossRefPubMed Jaikanth C, Gurumurthy P, Cherian KM et al (2013) Emergence of omentin as a pleiotropic adipocytokine. Exp Clin Endocrinol Diabetes 121:377–383CrossRefPubMed
34.
go back to reference Li XP, Zeng S, Wang M et al (2014) Relationships between serum omentin-1, body fat mass and bone mineral density in healthy Chinese male adults in Changsha area. J Endocrinol Invest 37(10):991–1000CrossRefPubMed Li XP, Zeng S, Wang M et al (2014) Relationships between serum omentin-1, body fat mass and bone mineral density in healthy Chinese male adults in Changsha area. J Endocrinol Invest 37(10):991–1000CrossRefPubMed
Metadata
Title
Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children
Authors
A. Ciresi
G. Pizzolanti
M. Leotta
V. Guarnotta
G. Teresi
C. Giordano
Publication date
01-09-2016
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 9/2016
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-016-0475-z

Other articles of this Issue 9/2016

Journal of Endocrinological Investigation 9/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.